WO2005064332A1 - 高活性型リゾホスファチジン酸およびそれを用いたスクリーニング方法 - Google Patents
高活性型リゾホスファチジン酸およびそれを用いたスクリーニング方法 Download PDFInfo
- Publication number
- WO2005064332A1 WO2005064332A1 PCT/JP2004/019241 JP2004019241W WO2005064332A1 WO 2005064332 A1 WO2005064332 A1 WO 2005064332A1 JP 2004019241 W JP2004019241 W JP 2004019241W WO 2005064332 A1 WO2005064332 A1 WO 2005064332A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lpa
- formula
- group
- configuration
- highly active
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 150
- 238000012216 screening Methods 0.000 title claims abstract description 57
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 title description 210
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 144
- 150000003839 salts Chemical class 0.000 claims abstract description 98
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 claims abstract description 94
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 claims abstract description 94
- 239000003814 drug Substances 0.000 claims abstract description 82
- 239000012453 solvate Substances 0.000 claims abstract description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 55
- 201000010099 disease Diseases 0.000 claims abstract description 53
- 229940002612 prodrug Drugs 0.000 claims abstract description 53
- 239000000651 prodrug Substances 0.000 claims abstract description 53
- 230000027455 binding Effects 0.000 claims abstract description 47
- 239000000126 substance Substances 0.000 claims abstract description 41
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 21
- 208000014001 urinary system disease Diseases 0.000 claims abstract description 14
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 7
- 208000026278 immune system disease Diseases 0.000 claims abstract description 6
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims description 74
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 41
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 38
- 230000036961 partial effect Effects 0.000 claims description 34
- 238000012360 testing method Methods 0.000 claims description 28
- 125000001931 aliphatic group Chemical group 0.000 claims description 25
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 230000003834 intracellular effect Effects 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 18
- 101000864393 Homo sapiens Protein BUD31 homolog Proteins 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 102100030160 Protein BUD31 homolog Human genes 0.000 claims description 14
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 11
- 229910001424 calcium ion Inorganic materials 0.000 claims description 11
- 230000019491 signal transduction Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 230000000069 prophylactic effect Effects 0.000 claims description 10
- 101001038001 Homo sapiens Lysophosphatidic acid receptor 2 Proteins 0.000 claims description 8
- 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 claims description 8
- 102100040387 Lysophosphatidic acid receptor 2 Human genes 0.000 claims description 8
- 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 101001038043 Homo sapiens Lysophosphatidic acid receptor 4 Proteins 0.000 claims description 6
- 102100040405 Lysophosphatidic acid receptor 4 Human genes 0.000 claims description 6
- 206010013990 dysuria Diseases 0.000 claims description 6
- 125000003700 epoxy group Chemical group 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 208000010643 digestive system disease Diseases 0.000 claims description 5
- 125000001867 hydroperoxy group Chemical group [*]OO[H] 0.000 claims description 5
- 239000000051 antiandrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 230000002280 anti-androgenic effect Effects 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229940123934 Reductase inhibitor Drugs 0.000 claims 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract description 12
- 230000003449 preventive effect Effects 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 97
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- 229940079593 drug Drugs 0.000 description 69
- -1 sphingosine monophosphate Chemical class 0.000 description 50
- 238000002360 preparation method Methods 0.000 description 45
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- 239000000243 solution Substances 0.000 description 27
- 102000005962 receptors Human genes 0.000 description 26
- 108020003175 receptors Proteins 0.000 description 26
- 239000003446 ligand Substances 0.000 description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 20
- 238000005259 measurement Methods 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 239000000872 buffer Substances 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 238000004113 cell culture Methods 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 239000012046 mixed solvent Substances 0.000 description 11
- 210000003708 urethra Anatomy 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- MHZDONKZSXBOGL-UHFFFAOYSA-N propyl dihydrogen phosphate Chemical compound CCCOP(O)(O)=O MHZDONKZSXBOGL-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 230000032050 esterification Effects 0.000 description 9
- 238000005886 esterification reaction Methods 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000825 pharmaceutical preparation Substances 0.000 description 7
- 230000000704 physical effect Effects 0.000 description 7
- 229940044601 receptor agonist Drugs 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 239000011668 ascorbic acid Substances 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940095074 cyclic amp Drugs 0.000 description 6
- 238000004807 desolvation Methods 0.000 description 6
- 230000001804 emulsifying effect Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000018 receptor agonist Substances 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 229940083542 sodium Drugs 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 150000001204 N-oxides Chemical class 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 102000011420 Phospholipase D Human genes 0.000 description 4
- 108090000553 Phospholipase D Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 206010046543 Urinary incontinence Diseases 0.000 description 4
- 208000012931 Urologic disease Diseases 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 238000007915 intraurethral administration Methods 0.000 description 4
- 239000007951 isotonicity adjuster Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- DZNKOAWEHDKBEP-UHFFFAOYSA-N methyl 2-[6-[bis(2-methoxy-2-oxoethyl)amino]-5-[2-[2-[bis(2-methoxy-2-oxoethyl)amino]-5-methylphenoxy]ethoxy]-1-benzofuran-2-yl]-1,3-oxazole-5-carboxylate Chemical compound COC(=O)CN(CC(=O)OC)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OC)CC(=O)OC)=CC2=C1OC(C=1OC(=CN=1)C(=O)OC)=C2 DZNKOAWEHDKBEP-UHFFFAOYSA-N 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 230000020477 pH reduction Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 4
- 229960003081 probenecid Drugs 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 230000001078 anti-cholinergic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 150000001924 cycloalkanes Chemical class 0.000 description 3
- 150000001925 cycloalkenes Chemical class 0.000 description 3
- SFZPXOCDWIEAMS-UHFFFAOYSA-L disodium;propyl phosphate Chemical compound [Na+].[Na+].CCCOP([O-])([O-])=O SFZPXOCDWIEAMS-UHFFFAOYSA-L 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- XGRLSUFHELJJAB-JGSYTFBMSA-M sodium;[(2r)-2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)([O-])=O XGRLSUFHELJJAB-JGSYTFBMSA-M 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000272875 Ardeidae Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 2
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000004287 Dehydroacetic acid Substances 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 102000036530 EDG receptors Human genes 0.000 description 2
- 108091007263 EDG receptors Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010036018 Pollakiuria Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- RXZMMZZRUPYENV-VROPFNGYSA-N Solifenacin succinate Chemical compound OC(=O)CCC(O)=O.C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 RXZMMZZRUPYENV-VROPFNGYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 2
- QDPOOGQUCJJZAO-FCXRPNKRSA-N [(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QDPOOGQUCJJZAO-FCXRPNKRSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- 229960002903 benzyl benzoate Drugs 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000000748 compression moulding Methods 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 2
- 229960002677 darifenacin Drugs 0.000 description 2
- 229940061632 dehydroacetic acid Drugs 0.000 description 2
- 235000019258 dehydroacetic acid Nutrition 0.000 description 2
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- SQKXYSGRELMAAU-UHFFFAOYSA-N imidafenacin Chemical compound CC1=NC=CN1CCC(C(N)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 SQKXYSGRELMAAU-UHFFFAOYSA-N 0.000 description 2
- 229950005396 imidafenacin Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000001802 myricyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000009935 nitrosation Effects 0.000 description 2
- 238000007034 nitrosation reaction Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 201000004240 prostatic hypertrophy Diseases 0.000 description 2
- 210000003689 pubic bone Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229950009846 scopolamine butylbromide Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 2
- 229940046307 sodium thioglycolate Drugs 0.000 description 2
- 229960003855 solifenacin Drugs 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229960003553 tolterodine tartrate Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960001530 trospium chloride Drugs 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- HHXYJYBYNZMZKX-UHFFFAOYSA-N 3,4:15,16-diepoxy-7-oxo-13(16),14-clerodadien-20,12-olide-(3alpha,4alpha)-form Natural products C12CCC3C4(C)CCCC(C)(C)C4CCC3(C)C1(C)CCC1C2(C)CCC1C(=C)C HHXYJYBYNZMZKX-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- TWHZNAUBXFZMCA-UHFFFAOYSA-N Acotiamide Chemical compound C1=C(OC)C(OC)=CC(O)=C1C(=O)NC1=NC(C(=O)NCCN(C(C)C)C(C)C)=CS1 TWHZNAUBXFZMCA-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Chemical class 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical class NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- KKTIOMQDFOYCEN-OFUYBIASSA-N Osaterone acetate Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 KKTIOMQDFOYCEN-OFUYBIASSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 102100031950 Polyunsaturated fatty acid lipoxygenase ALOX15 Human genes 0.000 description 1
- 101710164073 Polyunsaturated fatty acid lipoxygenase ALOX15 Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- QPCVHQBVMYCJOM-UHFFFAOYSA-N Propiverine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC)C(=O)OC1CCN(C)CC1 QPCVHQBVMYCJOM-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- MHLYRDUUOGMFOU-XJDOXCRVSA-N [(2S)-2-hydroxy-3-phosphonooxypropyl] 15-hydroperoxyoctadeca-9,12,16-trienoate Chemical compound CC=CC(OO)CC=CCC=CCCCCCCCC(=O)OC[C@H](O)COP(O)(O)=O MHLYRDUUOGMFOU-XJDOXCRVSA-N 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- WUBKMAXEHQTPBW-XPTPVYCOSA-N [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (2S)-2-(hydroxymethyl)-4-[(R)-methylsulfinyl]-2-phenylbutanoate hydrobromide Chemical compound Br.C1([C@@](CO)(C(=O)O[C@@H]2C3CCN(CC3)C2)CC[S@](=O)C)=CC=CC=C1 WUBKMAXEHQTPBW-XPTPVYCOSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical compound OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- 229950005462 acotiamide Drugs 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000004097 arachidonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical class OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical compound C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 description 1
- 229960000910 bethanechol Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- CHRHZFQUDFAQEQ-UHFFFAOYSA-L calcium;2-hydroxyacetate Chemical compound [Ca+2].OCC([O-])=O.OCC([O-])=O CHRHZFQUDFAQEQ-UHFFFAOYSA-L 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 125000003901 ceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 description 1
- 229960001399 clenbuterol hydrochloride Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 1
- 229960000220 doxazosin mesylate Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000002818 heptacosyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- MGCQZNBCJBRZDT-UHFFFAOYSA-N midodrine hydrochloride Chemical compound [H+].[Cl-].COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 MGCQZNBCJBRZDT-UHFFFAOYSA-N 0.000 description 1
- 229960002728 midodrine hydrochloride Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 125000002819 montanyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- HWMFFWCDLWDYGX-UHFFFAOYSA-N n-(4-aminophenyl)furan-2-carboxamide Chemical compound C1=CC(N)=CC=C1NC(=O)C1=CC=CO1 HWMFFWCDLWDYGX-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 125000002465 nonacosyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 208000024449 overflow incontinence Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 229960002386 prazosin hydrochloride Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- 229960003510 propiverine Drugs 0.000 description 1
- 229960001187 propiverine hydrochloride Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 description 1
- 229960004953 silodosin Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000022170 stress incontinence Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003198 tamsulosin hydrochloride Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001909 terazosin hydrochloride Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- the present invention relates to a novel substance, a highly active lysophosphatidic acid (hereinafter sometimes abbreviated as a highly active LPA), and lysophosphatidic acid (hereinafter, referred to as “highly active LPA”).
- LPA may be abbreviated.
- LPA which is one of the lipid mediators, is collectively referred to as lysolin lipid together with sphingosine monophosphate.
- LPA is a ligand for EDG (Endothelial differentiation gene)-a GPCR (receptor having a G protein-coupled seven transmembrane domain in the molecule) called 2, 4, and 7, and binds to these receptors
- EDG Endothelial differentiation gene
- GPCR receptor having a G protein-coupled seven transmembrane domain in the molecule
- lipid mediators functioning as GPCR ligands are not detected in blood of healthy organisms, or are detected in trace amounts, such as PAF (platelet activating factor) and leukotriene.
- PAF platelet activating factor
- LPA has been confirmed to be present at extremely high concentrations of several / zg and V / mL in mammalian serum.
- the ligand is in excess, it is expected that the LPA receptor is always in an active state.
- a chemically synthesized LPA receptor agonist is administered to a living body while exerting force, such receptor exhibits an activating effect similar to a general ligand receptor response.
- LPA receptors are normally inactivated, despite the excess of their ligand, LPA, for example.
- LPA its ligand responsible for the activation of the LPA receptor
- the ligand responsible for the activation of the LPA receptor is predicted to be another ligand other than LPA.
- Patent Document 1 International Publication No. 99Z24569 pamphlet
- Patent Document 2 International Publication No. 96Z39436 pamphlet
- An object of the present invention is to find a novel ligand other than LPA that is responsible for activating the LPA receptor in vivo, and to provide a high-sensitivity of a potent ligand and a substance that modulates their binding using the LPA receptor. To construct a screening system.
- LPA is more active, undergoes a modification such as acidification in vivo, and has a higher activity as a novel ligand for the LPA receptor.
- the present invention was completed by finding the fact that they function in combination and conducting further studies based on this finding.
- the present invention provides:
- the highly active LPA has the following general formula (1), (II) or ( ⁇ )
- R 1 represents an oxidized, nitrated, nitrosated, nitrohydridylated, Z- or aminated aliphatic hydrocarbon group or an aliphatic hydrocarbon carbonyl group.
- the asymmetric carbon may be in an R configuration or an S configuration, or may be mixed in any ratio.
- the compound according to the above [1] which is a compound thereof, a salt thereof or a solvate thereof.
- R ⁇ ⁇ is an aliphatic hydrocarbon group or an aliphatic hydrocarbon carbonyl group having at least one partial structure selected from the group Q below, wherein the group Q is
- the asymmetric carbon may be in an R configuration or an S configuration, or may be mixed in any ratio.
- an arrow represents a binding site
- Y represents a carboxyl group or a methylene group
- p and q each independently represent an integer of 0 or 1 to 7
- E 1 and E 2 represent Each independently represents a C14 alkylene group, a C2-4 alkylene group or a bond
- A represents a bond
- n represents an integer of 1 to 6.
- a plurality of EE 2 and A may be the same or different. Provided that at least one A in R 1 is
- an arrow represents a binding site
- Y represents a carboyl group or a methylene group
- pi and ql each independently represent an integer of 1 to 7
- T represents [0023]
- the arrow represents a bonding site, provided that the asymmetric carbon is an R-configuration, an S-configuration force, or a mixture thereof at an arbitrary ratio.
- R represents an integer of 1 to 5, and when r is 2 or more, a plurality of Ts may be the same or different. Where at least one T in R 1 is
- the asymmetric carbon is assumed to have an R configuration, an S configuration, or a mixture thereof at an arbitrary ratio.
- the LPA-related disease is a urinary disease, a central disease, an inflammatory disease, a circulatory disease, a cancer, a diabetes, an immune system disease, or a digestive system disease; 12] The method according to the above [11], wherein the urinary system disease is dysuria;
- kits for screening a substance for preventing and / or treating a disease associated with LPA which comprises using a highly active LPA which may be labeled;
- a urological disease comprising a compound, a salt thereof, a solvate thereof, or a prodrug thereof obtained using the method according to [1] and Z or the kit according to [13], Prophylactic and / or therapeutic agents for central, inflammatory, circulatory, cancer, diabetes, immune or digestive disorders;
- a diagnostic agent for a disease associated with LPA comprising the antibody according to the above [23];
- a method for producing a substance for preventing and / or treating LPA-related diseases which comprises a step of selecting a compound using the screening method according to [17].
- General formula (1), ( ⁇ ) or (III) synthesized chemically or enzymatically
- R 1 represents an oxidized, nitrated, nitrosated, nitrohydrylated or Z-amino group or an aminated aliphatic hydrocarbon group or an aliphatic hydrocarbon carbonyl group.
- the asymmetric carbon may be in an R configuration or an S configuration, or may be mixed in any ratio.
- the asymmetric carbon is an R-configuration, an S-configuration force, or a mixture thereof in an arbitrary ratio.
- R 1 represents an oxidized, nitrated, nitrosated, nitrohydrylated or Z- or aminated aliphatic hydrocarbon group or an aliphatic hydrocarbon carbonyl group.
- the asymmetric carbon may be in an R configuration or an S configuration, or may be mixed in any ratio.
- a cell culture composition comprising a compound represented by the formula (I), a salt thereof or a solvate thereof;
- composition according to the above [29] which is a cell differentiation controlling agent
- R 1 represents an oxidized, nitrated, nitrosated, nitrohydrylated, Z- or aminated aliphatic hydrocarbon group or an aliphatic hydrocarbon carbonyl group.
- the asymmetric carbon may be in an R configuration or an S configuration, or may be mixed in any ratio.
- LPA is a compound represented by the general formula (I), (II) or (III), wherein R 1 is an "unsubstituted aliphatic hydrocarbon group” or " It means a “substituted aliphatic hydrocarbon carbonyl group”, which may be either naturally occurring or non-naturally occurring.
- R 1 is an "unsubstituted aliphatic hydrocarbon group” or " It means a “substituted aliphatic hydrocarbon carbonyl group”, which may be either naturally occurring or non-naturally occurring.
- the “unsubstituted aliphatic hydrocarbon group” may be a linear group composed of only carbon atoms and hydrogen atoms, and examples thereof include an alkyl group, an alkenyl group, and an alkenyl group. It includes a rukinyl group and the like.
- the “unsubstituted aliphatic hydrocarbon group” may contain an alicyclic hydrocarbon group-like structure in the group.
- "Alicyclic hydrocarbon group-like structure” means a divalent group formed by removing any two hydrogen atoms from an alicyclic hydrocarbon such as a lower cycloalkane or a lower cycloalkene.
- Examples of the “lower cycloalkane” include cycloalkanes having 3 to 8 carbon atoms such as cyclopropane, cyclobutane, cyclopentane and cyclohexane.
- the “lower cycloalkene” includes, for example, carbon atoms such as cyclopropene, 1-cyclopentene, 2-cyclopentene, 3-cyclopentene, 1-cyclohexene, 2-cyclohexene, 3-cyclohexene and 3-cycloheptene. And 3 to 8 cycloalkenes.
- Examples of the aliphatic hydrocarbon group having an alicyclic hydrocarbon group-like structure in the group include a 7- (2-xylcyclopropyl) heptyl group and the like.
- alkyl group examples include, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, noel, decyl, pendecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecinole, And linear C1-30 alkyl groups such as icosinole, henicosinole, docosinole, tricosinole, tetracosinole, pentacosinole, hexacosyl, heptacosyl, octacosyl, nonacosyl and triacontyl.
- alkenyl group examples include, for example, etul, probenole, buteninole, penteninole, hexeninole, hepteninole, octeninole, noneninole, asenil, pendezell, dodecerl, tridisele , Tetradecer, pentadecer, hexadecer, heptadecer, octadecer, nonadecer, icoser, hecosininole, docoseninole, trichosininole, tetracosininole, pentacosinenole, hexacocinocenole, hexacosinocane And straight-chain C2-30 alkenyl groups such as octacosel, nonacosel and triacontyl groups.
- alkyl group examples include, for example, ethur, propinolone, butyninole, pentinole, hexininole, heptinole, otachininole, nonininole, desil, pendecyl, dodecyl, tridecyl.
- the "unsubstituted aliphatic hydrocarbon carbonyl group” means a monovalent group in which a carbonyl group is bonded to the "unsubstituted aliphatic hydrocarbon group”.
- LPA has a carbon number of the carbon chain constituting the R 1, with the number of double bonds in R 1, for example, carbon in the carbon chain constituting the R 1 If the number is 18 and the number of double bonds in R 1 is 1, it may be written as 18: 1—LPA.
- preferred LPAs include naturally occurring ones.
- LPA is preferably used according to the above-mentioned notation, for example, 16: 1-LPA, 18: 1-LPA, 18: 2-LPA, 18: 3—LPA, 20: 1—LPA, 20: 2—LPA, 20: 3—LPA, 20: 4—LPA, 20: 5—LPA, 22: 1—LPA, 22: 2—LPA, 22: 3— LPA, 22: 4-LPA, 22: 5-LPA, 22: 6-LPA and the like.
- LPAs are LPAs existing in living organisms of mammals, especially humans.
- the highly active LPA is a substance having a structure different from that of the LPA, binding to the LPA receptor, and having an activity substantially equal to or higher than that of the LPA.
- the structure is not limited as long as the structure shows.
- a substance exhibiting substantially the same or higher activity than LPA includes, for example, (1) a receptor binding activity, or (2) a signal signal transduction action, etc., which are known to those of LPA receptor.
- a material that is about 1 to about 10 times, preferably about 1 to about 100 times, more preferably about 1 to about 1000 times.
- a highly active LPA is not required to exhibit an activity exceeding LPA in all activity measurement systems. If at least one of the test systems capable of detecting the activity of LPA exhibits an activity exceeding LPA in at least one system, #2.
- the activity of the receptor-binding activity can be measured according to known methods. For example, it can be measured according to the screening method described later, the method described in the Examples, and the like. Monkey
- R 1 is oxidized, nitrated, nitrosated, nitrohydrylated and / or Or an aminated aliphatic hydrocarbon group or an aliphatic hydrocarbon carbonyl group.
- examples of the aliphatic hydrocarbon group include those exemplified as the “unsubstituted aliphatic hydrocarbon group”.
- the term "aliphatic hydrocarbon carbonyl group” means, for example, the same as the above-mentioned "unsubstituted aliphatic hydrocarbon carbonyl group”.
- Oxidation means that at least one oxygen atom is introduced into the target molecule (here, an aliphatic hydrocarbon group or an aliphatic hydrocarbon carbonyl group).
- O—O— oxygen-containing groups
- oxygen-containing groups such as formyl groups
- amino acid to be added is not particularly limited, and may be a peptide.
- an amino acid normally present in a living body for example, an ⁇ -amino acid or the like
- a peptide thereof, or the like is used.
- the number of amino acids constituting the peptide is not particularly limited.
- two or more Ten more preferably two to five, particularly preferably two (ie, dipeptide) to three (ie, tripeptide) and the like.
- Suitable amino acids to be “aminated” include, for example, cysteine, serine, glutathione, glycylcysteine, 5-glutamylcysteine and the like.
- oxidation the carbon chain of the aliphatic hydrocarbon group or the aliphatic hydrocarbon carboxyl group accompanies the “nitration”, “nitrosation”, “nitrohydrylation” and “amination”. It doesn't matter if is cut off.
- R 1 is
- an aliphatic hydrocarbon group having one or more partial structures selected from the group consisting of an aliphatic hydrocarbon group and an aliphatic hydrocarbon carbonyl group.
- an asymmetric carbon may be represented by using the symbol "*" as described above, but even without the symbol, a person skilled in the art can determine that an asymmetric carbon exists.
- the asymmetric carbon may have an R configuration, an S configuration, or a mixture thereof in an arbitrary ratio.
- more preferred high-activity LPAs include, for example, the aforementioned general formula (I),
- oxidized 22: 6-LPA, 20: 4-LPA, 18: 1-LPA, 18: 2-LPA, 18: 3-LPA, 16: 1-LPA are preferred.
- 20: 4-LPA, 18: 1-LPA, 18: 2-LPA, 18: 3-LPA and the like are more preferred.
- R 1 has 18 carbon atoms
- R 1 is -CHO or
- R 1 is [0062] [Formula 21]
- R 1 is -CH 0, -CH 0, -CH 0, -CH 0, or C
- R 1 is [0065]
- examples of the C14 alkylene group include a methylene, ethylene, trimethylene, tetramethylene group and isomer groups thereof.
- examples of the C2-4 alkylene group include eturene, probelene, butylene group, and isomer groups thereof.
- preferred, highly active LPA is also defined by the length of the carbon chain of R 1 it can.
- highly active LPA or carbon atoms in the main chain of R 1 is 6 to 26 Kodea shall like are also preferable.
- the carbon number of the main chain also includes the carbon carbon in the aliphatic hydrocarbon carboxy group. That is, oxidized, nitrated, nitrosated, nitrohydrylated and Z or aminated C6-26alkyl, C6-26alkyl, C6-26alkyl, C6-25alkylcarbo- And a C6-25 alkylcarbyl group and a C6-25 alkylcarbyl group are preferred. In particular, these oxidized groups are preferred.
- R 1 is more preferably, for example, one having 10 to 20 carbon atoms in the main chain, and particularly preferably one having 16 to 20 carbon atoms in the main chain. .
- the high-activity LPA can be obtained by the following method.
- it can be obtained by any method of (1) chemically synthesizing; (2) purifying a biological sample; (3) synthesizing enzymatically;
- a suitable oxidizing agent for example, metaclonal solvent
- any solvent containing LPA for example, water or an organic solvent (for example, chloroform, methanol, acetonitrile, etc.)).
- Perbenzoic acid, etc. is added to any solvent containing LPA (for example, water or an organic solvent (for example, chloroform, methanol, acetonitrile, etc.)).
- a suitable oxidizing agent for example, metaclonal solvent
- any solvent containing LPA for example, water or an organic solvent (for example, chloroform, methanol, acetonitrile, etc.)
- Perbenzoic acid, etc. perbenzoic acid, etc.
- the reaction between LPA and oxygen may be brought into contact with oxygen gas or air oxidation. Further, it may be reacted with dissolved oxygen in an arbitrary solvent.
- LPA is adsorbed to a suitable container (eg, a glass container such as an eggplant flask that can secure a certain surface area) and stored at an appropriate temperature (eg, room temperature) under a dry air stream, or Any solvent containing LPA (for example, water or an organic solvent (for example, chloroform, methanol, acetonitrile, etc.), etc.) can be used for any period (for example, 24 hours). (Time to several days) at an arbitrary temperature (preferably room temperature or the like).
- a suitable container eg, a glass container such as an eggplant flask that can secure a certain surface area
- an appropriate temperature eg, room temperature
- Any solvent containing LPA for example, water or an organic solvent (for example, chloroform, methanol, acetonitrile, etc.), etc.) can be used for any period (for example, 24 hours).
- a suitable container eg, a glass container such as an eggplant flask that can secure a certain surface area
- Purification of the biological sample strength is performed by subjecting a fraction obtained by a method such as gel filtration to a purification method such as silica gel column chromatography or reverse phase column chromatography.
- a purification method such as silica gel column chromatography or reverse phase column chromatography.
- the desired highly active LPA is obtained as a mixture by these methods, it can be isolated by a known purification method.
- isolation can be performed by silica gel chromatography using silica gel (eg, Merck7734 or the like) as a carrier and an appropriate solvent such as chloroform, methanol and a mixed solvent which also has hydrodynamic power.
- the biological sample for example, blood or the like can be suitably used.
- myelin peroxidase for example, myelin peroxidase, oxidase, 12 / 15-lipoxygenase, P450 metabolizing enzyme and the like can be used.
- LPA used as a raw material is obtained, for example, by enzymatically treating lysophosphatidylcholine with an enzyme, for example, phospholipase D or the like, as described in Reference Examples below, or Further, it can be obtained by subjecting it to the known purification method described above.
- an enzyme for example, phospholipase D or the like, as described in Reference Examples below, or Further, it can be obtained by subjecting it to the known purification method described above.
- the LPA receptor protein may be a receptor protein capable of binding to the above-mentioned LPA and capable of transmitting a signal into a cell expressing a strong receptor protein. It can be used without particular limitation.
- a receptor protein for example, known LPA receptor proteins such as EDG-2, EDG-4, EDG-7 and GPR23 are preferably used, but these proteins are substantially used. Proteins having the same activity or having an amino acid sequence substantially the same as the amino acid sequence of these proteins can also be used.
- EDG-2, EDG-4, and EDG-7 are sometimes referred to as LPA1, LPA2, and LPA3, respectively.
- proteins having substantially the same activity includes, for example, a protein having a similar property of a ligand-binding activity, a signal transduction action and the like. Therefore, proteins having substantially the same activity include those having the ligand binding activity and signal transduction activity, etc., having the above-mentioned known receptor proteins, ie, EDG-2, EDG-4, EDG- 7 and GPR23 (e.g., about 0. (01 to about 100 times, preferably about 0.5 to about 20 times, more preferably about 0.5 to about 2 times). The quantitative factors are different.
- the activity such as the ligand binding activity and the signal transduction activity can be measured according to a force that can be performed according to a known method, for example, according to a screening method described later.
- protein having substantially the same amino acid sequence includes, for example, about 50% of the amino acid sequence of the known receptor protein, ie, the protein such as EDG-2, EDG-4, EDG-7 and GPR23. % Or more, preferably about 60% or more, more preferably about 70% or more, still more preferably about 80% or more, particularly preferably about 90% or more, and most preferably about 95% or more. And the like.
- the above-mentioned LPA receptor protein is not limited to its origin.
- all cells of human mammals eg, guinea pig, rat, mouse, egret, pig, sheep, wedge, monkey, etc.
- spleen cells nerve cells, glial cells, spleen j8 cells, bone marrow cells, mesangium
- Cells Langerhans cells, epidermal cells, epithelial cells, endothelial cells, fibroblasts, fiber cells, muscle cells, adipocytes, immune cells (e.g., macrophages, T cells, B cells, natural killer cells, mast cells, neutrophils Basophils, eosinophils, monocytes, etc.), megakaryocytes, synovial cells, chondrocytes, osteocytes, osteoblasts, osteoclasts, mammary cells, hepatocytes or stromal cells, or these Progenitor cells,
- LPA receptor protein of the present invention in addition to the above-mentioned LPA receptor protein, some amino acids are modified, such as addition, deletion and Z or substitution, to their amino acid sequences. Or a receptor protein containing the amino acid sequence.
- the LPA receptor protein in the present invention can be substituted, if desired, with an arbitrary functional group (for example, a carboxyl group, an amino group, a hydroxyl group, a thiol group, etc.) in the molecule to such an extent that the function as a receptor is not lost. It may be substituted by a group, or a sugar chain may be attached.
- the partial peptide of the receptor protein includes a partial peptide of the receptor protein or an amino acid substantially identical to the partial peptide.
- the peptide may be any peptide having a sequence, but is preferably a site of the receptor protein molecule that is exposed outside the cell membrane and has substantially the same ligand binding property. Those having activity or the like are used.
- the above-mentioned known receptor proteins, that is, partial peptides such as EDG-2, EDG-4, EDG-7 and GPR23 include, for example, an extracellular region (hydrophilic site) in a hydrophobic plot analysis.
- the number of amino acids in the partial peptide used in the present invention is preferably at least 20 or more, preferably 50 or more, more preferably 100 or more in the amino acid sequence constituting the receptor protein.
- the “substantially identical amino acid sequence” is about 50% or more, preferably about 60% or more, more preferably about 70% or more, even more preferably the amino acid sequence of the partial peptide of the receptor protein.
- substantially the same ligand binding activity means the same nature of the ligand binding activity, and can be measured in the same manner as the above-mentioned receptor protein ligand binding activity.
- the partial peptide in the present invention contains, in addition to the partial peptide described above, an amino acid sequence in which some amino acids have been modified, such as addition, deletion and / or substitution, with respect to their amino acid sequences. Partial peptide or the like.
- the partial peptide in the present invention may have any desired position so that any functional group (eg, carboxyl group, amino group, hydroxyl group, thiol group, etc.) in the molecule does not lose ligand binding activity, if desired. It may be substituted by a substituent or a sugar chain may be bonded.
- examples of the salt of the receptor protein or its partial peptide include a physiologically acceptable salt with an acid or a base, and particularly a physiologically acceptable acid.
- Addition salts and the like are preferred.
- examples of such salts include salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, etc.) and organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid,
- salts with succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid and the like are used.
- the above-mentioned LPA receptor protein, its partial peptide or its salt can be obtained by a known method.
- the LPA receptor protein or a salt thereof according to the present invention can be produced by the above-described method for purifying a receptor protein of known human or mammalian cell or tissue strength. Alternatively, it can be produced by culturing a transformant containing a DNA encoding a strong receptor protein. Furthermore, it can also be produced by a known protein synthesis method or a method analogous thereto.
- Methods for obtaining the LPA receptor protein include, for example, WO97Z00952 pamphlet, WO96Z39436 pamphlet, JP-A-10-210993, JP-A-11-18788, WO99Z29887, WO It is described in detail in pamphlet No. 99/24569 and the like.
- the human or mammalian tissues or cells are homogenized and then extracted with an acid or the like, and the resulting extract is subjected to reverse phase chromatography, ion exchange chromatography, or the like. Purification and isolation can be achieved by combining chromatography.
- the partial peptide or a salt thereof according to the present invention can be produced according to a known peptide synthesis method or by cleaving the protein of the present invention with an appropriate peptidase.
- a peptide synthesis method for example, a solid phase synthesis method, a liquid phase synthesis method, or the like can be used.
- a labeling substance used for labeling high-activity LPA for example, a radioisotope
- an enzyme for example, a fluorescent substance, a luminescent substance and the like
- a radioactive isotope for example, 125 ⁇ , 131 ⁇ , 3 ⁇ 4 , 14 C, 32 P or the like
- the enzyme for example, ⁇ -galactosidase, j8-dalcosidase, alkaline phosphatase, peroxidase, malate dehydrogenase and the like are used.
- the fluorescent substance include fluorescamine, Fluorescein isothiosinate and the like are used.
- luminescent substance for example, luminol, luminol derivative, luciferin, lucigenin and the like are used.
- the highly active LPA of the present invention is safe and has low toxicity, it can be used as a screening tool!
- the screening method of the present invention is characterized by using (1) a highly active LPA which may be labeled, and (2) an LPA receptor protein, a partial peptide thereof or a salt thereof.
- a substance having a specific function is found using these substances, for example, a substance for preventing and / or treating a disease associated with LPA, the substance is included in the present invention.
- the screening method of the present invention comprises, for example, (a) contacting (a) a highly active LPA which may be labeled with (b) an LPA receptor protein, a partial peptide thereof or a salt thereof, (2) A comparison is made between (a) highly active LPA, which may be labeled, and (b) an LPA receptor protein, its partial peptide or a salt thereof, and (c) a test compound.
- the LPA receptor protein, its partial peptide or its salt used in the screening method of the present invention impairs the ligand binding activity and may be in any state. For example, it may be in an isolated state or in a state of being expressed in a cell.
- a vigorous cell force may be in the state of the prepared membrane fraction, and further, a living body (for example, a mammal) may be used.
- the method for measuring the binding between the LPA receptor protein, its partial peptide or its salt and the highly active LPA ligand is a powerful LPA receptor protein, its partial peptide or its salt.
- a binding assay can be used.
- a phenomenon that occur in the cell e.g., increase or decrease in intracellular cyclic AMP (cAMP) or calcium ion concentration, increase or decrease in specific protein or mRNA encoding it, or Secretion of specific proteins to the outside
- cAMP intracellular cyclic AMP
- calcium ion concentration increase or decrease in specific protein or mRNA encoding it, or Secretion of specific proteins to the outside
- a mammal eg, mouse, rat, dog, etc.
- a phenomenon occurring in such a living body can be used as an index.
- the biopower can also be evaluated using a specific tissue extracted. For example, a Magnus test using the trachea or other smooth muscle or the intestinal tract may be used.
- preferable screening methods include, for example, the following methods [I] to [IV].
- a screening method comprising: [II] (l) (a) the case where a labeled high-activity type LPA is brought into contact with (b) the LPA receptor protein, its partial peptide or a salt thereof; When the active LPA is brought into contact with (b) an LPA receptor protein, a partial peptide or a salt thereof, and (c) a test compound, the labeled LPA receptor protein of the highly active LPA, A screening method comprising measuring and comparing the amount of binding to a partial peptide or a salt thereof.
- [IV] (1) When (a) labeled high-activity type LPA is brought into contact with (b) the membrane fraction of cells containing LPA receptor protein, and (2) (a) labeled Highly active LPA, (b) membrane fraction of cells containing LPA receptor protein, and (c) the membrane of labeled high active LPA cells when contacted with a test compound
- a screening method comprising measuring and comparing the amount of binding to a fraction.
- the measurement of the amount of binding that is, the activity of increasing the intracellular calcium ion concentration of bound Atsushi cells, can be measured using a known method or a commercially available measurement kit.
- cells containing LPA receptor protein or cells containing LPA receptor protein may be used.
- the cells may be fixed with dartalaldehyde, formalin or the like before use.
- the fixing method can be performed according to a known method.
- a cell containing the LPA receptor protein a host cell expressing the LPA receptor protein or the like is suitably used.
- the host cell is preferably Escherichia coli, Bacillus subtilis, yeast, insect cells, animal cells and the like.
- normal cells can be used as long as they are applicable to the LPA receptor protein expression level screening system.
- the cell membrane fraction refers to a fraction abundant in cell membrane obtained by disrupting cells and then obtained by a known method.
- Cells can be crushed by crushing the cells with a Potter-Elvehjem homogenizer, crushing with a Waring Blender / Polytron (manufactured by Kinematica), crushing with ultrasonic waves, or pressing cells with a French press or the like. Squirting from the fine zuzzles.
- fractionation by centrifugal force such as fractionation centrifugation or density gradient centrifugation is preferably used.
- the cell lysate is centrifuged at a low speed (for example, about 500 rpm to about 3000 rpm) for a short time (for example, about 1 minute to about 10 minutes), and the supernatant is further processed at a higher speed (for example, about 15000 rpm to about 30,000 rpm). Centrifugation for about 30 minutes to about 2 hours, and the resulting precipitate is used as a membrane fraction.
- the membrane fraction is rich in the expressed LPA receptor protein and membrane components such as cell-derived phospholipids and membrane proteins.
- the amount of the LPA receptor protein in the cells or membrane fraction containing the LPA receptor protein is preferably 10 3 to 10 8 molecules per cell, more preferably 10 5 to 10 7 molecules per cell. It is.
- the compounds obtained by the screening method of the present invention and exhibiting LPA receptor binding activity include agonists and antagonists of LPA receptor.
- LPA receptor agonists or antagonists from a group of compounds exhibiting LPA receptor binding activity, for example, (1) confirm the presence or absence of a signal signaling effect of the compound alone; (2) If LPA or highly active LPA is added in the presence of the compound, the presence or absence of a signal signal transduction effect is confirmed;
- the presence / absence of a signal signal transduction action refers to, for example, a phenomenon occurring in a cell or a phenomenon occurring in a tissue or a living body, as described above. It can be confirmed by setting a target.
- the kit for labeling ! which is characterized by using a highly active LPA, which is a kit for the prevention of diseases associated with LPA and the screening of Z or therapeutic substances, comprises: However, it is composed mainly of highly active LPA and (b) cells containing LPA receptor protein or its membrane fraction.
- the screening kit of the present invention include, for example, the following.
- Measurement buffer and washing buffer Hanks' Balanced Salt Solution (manufactured by Gibco) plus 0.05% serum albumin (manufactured by Sigma) and the like. The solution may be sterilized by filtration through a 0.45 ⁇ m filter and stored at 4 ° C, or may be prepared at use.
- LPA receptor protein preparation Chinese Hamster Ovary (CHO) cells expressing the LPA receptor protein were subcultured on a 12-well plate at 5 ⁇ 10 5 cells. , 37 ° C, 5% CO, 95% air
- (C) labeled high-activity LPA a commercially available solution containing high-activity LPA labeled with [], [ 12 ], [ 14 C], [ 35 S] or the like. Store at 4 ° C or 20 ° C, and dilute to 1 ⁇ with buffer solution for use before use.
- the labeled high-activity LPA bound to the cells is dissolved in 0.2N NaOH-1% SDS, and mixed with 4 mL of liquid scintillator A (Wako Pure Chemical Industries).
- PMB represents the Percent Maximum Binding
- B represents the value obtained when the sample is dried
- NSB represents Non-specific Binding (non-specific binding amount)
- B0 represents the maximum binding amount.
- the antibody against highly active LPA may be any of a polyclonal antibody and a monoclonal antibody as long as it can recognize the highly active LPA! / ⁇ .
- the antibody against the highly active LPA of the present invention comprises (1) a highly active LPA of the present invention, (2) a complex of the highly active LPA and a carrier protein, or (3) a highly active amino-carboxyl group. It can be produced according to a known method for producing an antibody or antiserum using a complex of a derivative having a type LPA side chain and a carrier protein as an antigen. An example of a specific method is shown below.
- the highly active LPA of the present invention is administered to a mammal alone or together with a carrier or diluent.
- Complete Freund's adjuvant—incomplete Freund's adjuvant may be administered in order to enhance the antibody-producing ability upon administration.
- the administration is usually performed once every 2 to 6 weeks, for a total of about 2 to 10 times.
- mammals to be used for example, power mice and rats including monkeys, egrets, dogs, guinea pigs, mice, rats, sheep, goats and the like are preferably used.
- the administration site is not particularly limited, and may be any site capable of producing an antibody.
- Monoclonal antibody-producing cells were prepared by selecting a warm-blooded animal immunized with the antigen, for example, an individual whose antibody titer was also recognized as a mouse, and sampling the spleen or lymph nodes 2 to 5 days after the final immunization.
- the monoclonal antibody-producing hybridoma can be prepared by fusing the antibody-producing cells contained in the above with myeloma cells.
- the antibody titer in antisera can be measured, for example, by reacting the labeled high-activity LPA with antiserum and then measuring the activity of a labeled substance bound to the antibody. You.
- the fusion operation with myeloma cells can be performed according to a known method, for example, the method of Koehler and Milstein [Nature, 256, 495 (1975)].
- PEG polyethylene glycol
- Sendai virus is preferred.
- the myeloma cell is preferably a force P3U1, such as NS-1, P3U1, SP2Z0, or the like.
- the preferred ratio between the number of antibody-producing cells (spleen cells) and the number of myeloma cells used is about 1: 1 to 20: 1, and PEG (preferably, PEGIOOO to PEG6000) is added at a concentration of about 10 to 80%.
- Cell fusion can be performed efficiently by incubating the mixture and incubating at about 20 to 40 ° C, preferably about 30 to 37 ° C for about 1 to 10 minutes.
- an antigen that is, a solid phase (for example, a microplate or the like) on which a highly active LPA is adsorbed directly or together with a carrier can be used.
- a method for detecting a monoclonal antibody bound to a solid phase adding a hybridoma culture supernatant to a solid phase to which an anti-immunoglobulin antibody or protein A is adsorbed, and adding a receptor protein labeled with a radioactive substance, an enzyme, etc. And a method for detecting a monoclonal antibody bound to a solid phase.
- Monoclonal antibodies can be selected according to a known method or a method analogous thereto. Usually, an animal cell culture medium or the like to which HAT (hypoxanthine, aminopterin, thymidine) is added can be used. As a selection and breeding medium, any medium can be used as long as it can grow a hybridoma.
- RPMI-1640 medium containing 1 to 20%, preferably 10 to 20% fetal bovine serum, GIT medium (Wako Pure Chemical Industries) containing 1 to 10% fetal bovine serum, or serum-free for hybridoma culture A medium (SFM-101, manufactured by Nissui Pharmaceutical Co., Ltd.) or the like can be used.
- the culture temperature is usually 20 to 40 ° C, preferably about 37 ° C.
- the culture time is usually 5 days to 3 weeks, preferably 1 week to 2 weeks.
- the culture can be usually performed under 5% carbon dioxide gas.
- the antibody titer of the hybridoma culture supernatant can be determined in the same manner as in the measurement of the antibody titer in the antiserum described above.
- Separation and purification of the monoclonal antibody can be performed according to the immunoglobulin separation and purification method in the same manner as ordinary separation and purification of polyclonal antibodies.
- Such purification methods include: For example, salting out method, alcohol precipitation method, isoelectric point precipitation method, electrophoresis method, adsorption / desorption method using an ion exchanger (for example, DEAE), ultracentrifugation method, gel filtration method, antigen-binding solid phase, or A specific purification method in which only an antibody is collected with an active adsorbent such as mouth tin A or protein G and the bond is dissociated to obtain the antibody is used.
- an active adsorbent such as mouth tin A or protein G
- the polyclonal antibody can be produced according to a known method or a method analogous thereto.
- a complex of a highly active LPA, which is an immunizing antigen, and a carrier protein is formed, and a mammal is immunized in the same manner as in the above-described method for producing a monoclonal antibody. It can be produced by collecting a substance containing an antibody against type LPA and separating and purifying the antibody.
- the type of carrier protein and the mixing ratio of the carrier and the hapten are determined by the efficiency of the antibody against the hapten immunized by crosslinking with the carrier.
- Any material can be crosslinked at any ratio as long as it can be prepared.
- serum albumin, thyroglobulin, keyhole 'Limpet' hemocyanin, etc. are added in a weight ratio.
- a method of coupling the hapten 1 at a ratio of about 0.1 to about 20, preferably about 1 to about 5 is used.
- a dartartaldehyde carbodiimide capable of using various condensing agents, a maleimide active ester, an active ester reagent containing a thiol group or a dithioviridyl group.
- the condensation product is administered alone or together with a carrier or diluent to a mammal.
- the administration site is not particularly limited as long as it is a site where antibody production is possible.
- Complete Freund's adjuvant or incomplete Freund's adjuvant may be administered in order to enhance the antibody-producing ability upon administration. Administration is usually
- the polyclonal antibody can be collected preferably from the blood, ascites, etc. of the aforementioned immunized mammal, preferably by blood.
- the polyclonal antibody titer in the antiserum can be measured in the same manner as the measurement of the antibody titer in the serum described above.
- the separation and purification of the polyclonal antibody can be performed according to the same immunoglobulin separation and purification method as the above-mentioned separation and purification of the monoclonal antibody.
- an antibody against high-activity LPA can specifically recognize high-activity LPA, it is useful for quantification of high-activity LPA in a test solution, particularly for quantification by sandwich immunoassay.
- the antibody against high-activity LPA of the present invention can be used, for example, for diagnosis of diseases and the like. For example, the amount of highly active LPA in a biological sample (preferably, tissue at the lesion site, blood, etc.) collected from a patient with a certain disease is measured and compared with the amount of highly active LPA in a normal tissue or healthy sample. By doing so, it is possible to determine whether or not the potential disease is a potential LPA-related disease.
- the disease is a disease involving LPA
- LPA obtained using the following neutralizing antibody or the screening method or the screening kit of the present invention can be used.
- the disease can be effectively treated.
- the screening method or screening kit of the present invention By administering the preventive substance for the LPA-related disease, the onset of the LPA-related disease can be effectively prevented.
- a neutralizing antibody against highly active LPA refers to a function of inhibiting the binding of highly active LPA to the LPA receptor protein and transmitting a signal from the LPA receptor protein.
- protein e.g., arachidonic acid release, acetylcholine release,
- high-activity LPA can be used in the above-described screening method, the above-mentioned antibody preparation, and the like, and can also be mixed with a commonly used basal medium for cell culture to perform cell culture.
- a composition for use Since the cell culture composition containing highly active LPA has an effect as a cell sorting control agent, for example, undifferentiated cells It can be differentiated into cells having a specific function (differentiation-inducing action), or can suppress the phenomenon that undifferentiated cells autonomously or heterogeneously shunt (shuffle-inhibiting action).
- an undivided cell is a cell that expresses the above-mentioned LPA receptor protein and that can be proliferated by a specific stimulus and has a specific function by a specific stimulus.
- Possible cells not limited by their origin.
- the origin of the cells is preferably an animal, especially a mammal, and more preferably a human.
- embryonic stem cells For example, embryonic stem cells, ectodermal stem cells, mesodermal stem cells, endodermal stem cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells, neural progenitor cells, hepatic stem cells, muscle stem cells, splenic stem cells, skin stem cells, retinal stem cells, Cells such as hair follicle stem cells, osteoprogenitor cells, adipose precursor cells, chondrocytes, hair matrix cells, epithelial cells, vascular endothelial cells, smooth muscle cells, and the like, as well as cells in the cell lineage of these cells. It is preferably used.
- the basal medium for cell culture used for mixing with the highly active LPA is not particularly limited.
- Dulbecco's modified Eagle medium, Williams E medium, Ham's F-10 medium, F-12 medium, Conventionally known media such as RPMI-1640 medium, MCDB153 medium, and 199 medium can be used as a basic medium for cell culture.
- an antibiotic / antifungal substance can be added to the cell culture basal medium, if desired.
- the basal medium for cell culture may further contain serum (eg, fetal bovine serum (FBS), bovine serum (Horse Serum), etc.), insulin, EGF, FGF2, bFGF, interleukin (IL) , Stem cell growth factor (SCF), erythropoietin (EPO), interferon (IFN), thrombopoietin (TPO), tumor necrosis factor (TNF), colony stimulating factor (CSF), dexamethasone, j8-glycerol phosphate, Additives such as ascorbic acid, TGF-j8, 1-methyl-3-isobutylxanthine, indomethacin, and the like, which have an activity of inducing self-partitioning, can also be appropriately added.
- serum eg, fetal bovine serum (FBS), bovine serum (Horse Serum), etc.
- insulin e.g, fetal bovine serum (FBS), bovine serum (Hors
- the concentration, time to act, cell density, and other culture conditions of high active LPA (for example, And the like) can be appropriately changed according to the type of cells to be cultured!
- a method for determining whether or not the cells cultured by the cell culture composition containing the highly active LPA have a divided force can be performed by a known method. For example, It is preferable to detect proteins, mRNAs, and the like that the cultured cells characteristically express according to the respective differentiation stages, using as an index.
- Cells cultured using the cell culture composition containing highly active LPA can be used for various purposes.
- cells for cell transplantation can be prepared by culturing and differentiating undifferentiated cells collected from a living body using a cell culture composition containing highly active LPA.
- the alkyl group, alkoxy group, alkylene group and the like include straight-chain and branched ones.
- isomers (E, Z, cis, trans) in double bonds, rings and fused rings isomers due to the presence of asymmetric carbon (R, S, ⁇ , j8, enantiomer, diastereomer), Optically active substance with optical activity (D, L, d, 1 body), polar form by chromatographic separation (high polar form, low polar form), equilibrium conjugate, mixture of these at any ratio, racemic mixture Objects are all included in the present invention.
- all isomers due to tautomerism are also included.
- a carbon atom serving as an asymmetric center may be indicated by adding *.
- the carbon atoms marked with * may be in the R configuration, in the S configuration, or they may be mixed in any ratio.
- the asymmetric carbon may have an R configuration, an S configuration, or a mixture of these at an arbitrary ratio. You can do it.
- the binding site may be indicated by an arrow.
- the direction of the structure having two or more arrows is not limited as long as the arrows are connected to a position where the arrows can be connected.
- [0108] indicates that it is connected to the near side of the paper (that is, ⁇ arrangement),
- [0110] represents an ⁇ -configuration, a / 3-configuration or a mixture thereof in any ratio
- [0112] represents that the mixture is in a mixture at an arbitrary ratio between the ⁇ configuration and the j8 configuration.
- Salts of the compounds derived according to the present invention include all pharmacologically acceptable ones.
- the pharmaceutically acceptable salts are preferably non-toxic and water-soluble. Suitable salts include, for example, salts of alkali metals (eg, potassium, sodium, lithium, etc.), salts of alkaline earth metals (eg, calcium, magnesium, etc.), and ammonium salts (eg, tetramethylammonium).
- the N-aged oxide form of the compound derived by the present invention The nitrogen atom of the compound guided by Ming represents that it has been oxidized. Further, the N-aged oxide form of the compound derived according to the present invention may further form the above-mentioned salt.
- the quaternary ammonium salt of the compound derived by the present invention is a compound wherein the nitrogen atom of the compound derived by the present invention is a group (wherein the group is an aliphatic hydrocarbon group which may have a substituent, Represents a cyclic group which may have.) Represents a quaternized group.
- the quaternary ammonium salt of the compound derived by the present invention may further form the above-mentioned salt or the above-mentioned N-oxide.
- Suitable solvates of the compound derived from the present invention, a salt thereof, an N-oxide thereof, and a quaternary ammonium salt thereof include, for example, a solvent such as water, an alcohol solvent (e.g., ethanol) and the like. Japanese products and the like.
- the solvate is non-toxic and water-soluble.
- the compounds derived by the present invention can be converted to the above-mentioned salts, the above-mentioned N-oxides, the above-mentioned quaternary ammonium salts, and the above-mentioned solvates by known methods.
- the highly active LPA of the present invention may be in the form of a salt or may be a solvate.
- these salts and solvates those similar to the salts and solvates of the compounds obtained using the above-described screening method or screening kit of the present invention are preferably used.
- a prodrug of a compound derived by the present invention refers to a compound that is converted into a compound derived by the present invention by a reaction with an enzyme, gastric acid, or the like in a living body.
- a prodrug of the compound derived by the present invention for example, when the compound derived by the present invention has an amino group, a compound wherein the amino group is acylated, alkylated or phosphorylated (for example, the present invention The amino group of the compound derived from the compound is converted to eicosayl, aryl, pentylaminocarboxy, (5-methyl-2-oxo-1,3-dioxolen-4-yl) methoxycarbyl, tetrahydrofuran -Hydroxylation, pyrrolidylmethyl dianilide, bivaloyloxymethylation, acetooxymethylation, tert-butyl dianilide, etc.); when the compound derived by the compound derived
- Alkylated, phosphorylated, and borated compounds for example, when the hydroxyl group of the compound derived by the present invention is acetylated, palmitoylated, I le of, pivaloyl reduction, illusion two
- the carboxy group is esterified or amidated.
- the prodrug of the compound derived by the present invention may be either a hydrate or a non-hydrate.
- the prodrug of the compound derived by the present invention can be derived by the present invention under physiological conditions as described in Hirokawa Shoten 1990, “Development of Pharmaceuticals,” Vol. 7, “Molecular Design,” pp. 163 to 198. May be changed to a compound.
- the compounds derived according to the present invention may be labeled with isotopes (eg, 3 H, “C, 35 S, 1251, etc.) and the like.
- a salt thereof, a solvate thereof, or a prodrug thereof may be a mammal (eg, a human, non-human animal such as a monkey, a higgin, a puppy, a puppy, a dog, a cat, a puppy, a rat, a mouse, etc.) )
- LPA lipoprotein
- the compound, a salt thereof, a solvate thereof, or a prodrug thereof obtained by using the screening method or the screening kit of the present invention is particularly useful for prevention and Z or treatment of urological diseases.
- Useful because LPA receptor agonists contract the urethra, urinary incontinence (e.g., stress incontinence due to impaired urethral function, dementia incontinence, reflex incontinence, overflow incontinence, urge incontinence, total incontinence) , Functional urinary incontinence, overflow urinary incontinence, etc.) and is useful for Z or treatment, and LPA receptor antagonist relaxes the urethra To prevent urethra and prostate contraction, and make urination difficult (e.g., delay in urination start, prolong urination time, small urine line, intermittent urination, two-stage urination, etc.), urine retention, urinary frequency, nocturia, etc.
- urinary incontinence
- the "disease involving LPA” is not limited to the diseases listed above, and is a disease in which LPA is known to be involved in formation, exacerbation and Z or continuation of the disease, and involvement of LPA. Include all diseases to be found in the future.
- the antibody against highly active LPA of the present invention in particular, a neutralizing antibody may be used as a diagnostic agent, or may be used for signal transduction involving highly active LPA and Z or LPA receptor, for example, Cell stimulating activity via LPA receptor protein (e.g., arachidonic acid release, acetylcholine release, increased intracellular calcium ion concentration, intracellular cyclic AMP (cAMP) generation, intracellular cyclic GMP (cGMP) generation, inositol Phosphoric acid production, cell membrane potential fluctuations, intracellular protein phosphorylation, activation of c fos, activity to promote or suppress pH reduction, etc.).
- LPA receptor protein e.g., arachidonic acid release, acetylcholine release, increased intracellular calcium ion concentration, intracellular cyclic AMP (cAMP) generation, intracellular cyclic GMP (cGMP) generation, inositol Phosphoric acid production, cell membrane potential fluctuations, intracellular protein phosphorylation, activ
- a salt thereof, a solvate thereof, or a prodrug thereof (For example, humans and non-human animals such as monkeys, higgs, lions, pomeras, dogs, cats, puppies, rats, mice, etc.) to prevent the above-mentioned diseases involving LPA and It can be used as a therapeutic agent.
- a salt thereof, a solvate thereof, or a prodrug thereof (For example, humans and non-human animals such as monkeys, higgs, lions, pomeras, dogs, cats, puppies, rats, mice, etc.) to prevent the above-mentioned diseases involving LPA and It can be used as a therapeutic agent.
- the antibody against the highly active LPA of the present invention it may be performed according to a general formulation of an antibody medicine.
- the compound in order to use the compound derived from the present invention, a salt thereof, a solvate thereof, or a prodrug thereof for the above-mentioned purpose, the compound is usually orally or parenterally administered as a pharmaceutical composition systemically or locally. It is administered in the form of
- the dosage varies depending on the age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc. Usually, the dosage is in the range of lmg to lOOOOmg per adult, once a day, and several times a day. Oral administration or parenteral administration (preferably intravenous), once to several times a day, in the range of lmg to 100mg / dose per adult, or 1 hour / day Or It is continuously administered intravenously for 24 hours.
- the dose varies depending on various conditions, and therefore, the dose may be smaller or larger than the above-mentioned dose, or may be necessary beyond the range.
- a salt thereof, a solvate thereof, or a prodrug thereof When administering the compound derived from the present invention, a salt thereof, a solvate thereof, or a prodrug thereof, according to a method known per se which is generally used in a method for producing a pharmaceutical preparation,
- the compound derived by the present invention, a salt thereof, a solvate thereof, or a prodrug thereof may be used as it is or in the form of a mixture with a pharmacologically acceptable carrier, for example, a solid preparation for internal use (for example, tablets (sugar-coated tablets, (Including film-coated tablets), powders, pills, granules, capsules, etc.), liquid preparations for internal use, liquid preparations for external use, injections, suppositories, sustained release, etc.
- a solid preparation for internal use for example, tablets (sugar-coated tablets, (Including film-coated tablets), powders, pills, granules, capsules, etc.
- the content of the compound derived from the present invention in a vigorous preparation may range from about 0.01% to about 100% by weight of the whole preparation, preferably from about 0.1% to about 50% by weight, more preferably , From about 0.5% to about 20% by weight.
- the compounds derived from the present invention used in the production of these pharmaceutical preparations are not limited to those that are substantially pure and a single substance, but may be impurities (for example, by-products derived from the production process). , A solvent, a raw material, or a degradation product, etc.) as long as the drug substance is acceptable.
- Pharmacologically acceptable carriers used in the production of these pharmaceutical preparations include various organic or inorganic carrier substances commonly used as preparation materials, such as excipients in solid preparations, lubricants and the like. Examples include powders, binders and disintegrants, or solvents in liquids, dissolution aids, emulsifying or suspending agents, isotonic agents, buffers and soothing agents. Further, if necessary, usual additives such as preservatives, antioxidants, coloring agents, sweeteners, adsorbents, wetting agents and the like can be used in appropriate amounts.
- Examples of the solid preparation for oral administration for oral administration include tablets, pills, capsules, powders, and granules.
- Capsules include hard capsules and soft capsules.
- one or more of the active substances may be intact or excipients (eg, ratatose, mannitol, glucose, microcrystalline cellulose, starch, corn starch, light caffeic anhydride, etc.).
- a binder for example, hydroxypropyl Lurose, polybutylpyrrolidone, magnesium aluminate metasilicate, crystalline cellulose, sucrose, D-mantol, dextrin, hydroxypropylmethylcellulose, starch, sucrose, gelatin, methylcellulose, sodium carboxymethylcellulose, etc.
- disintegrants eg fiber
- lubricants eg, magnesium stearate, calcium stearate, talc, colloidal silica, etc. It is formulated and used according to the usual method.
- a coating agent eg, sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, etc.
- a coating agent eg, sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, etc.
- capsules made of a material that can be absorbed, such as gelatin may be used.
- Liquid preparations for oral administration include pharmaceutically acceptable solutions, suspensions, emulsions, syrups, elixirs and the like.
- viscous solutions one or more active substances are dissolved, suspended or emulsified using commonly used diluents (eg, purified water, ethanol or a mixture thereof).
- the solution may further contain a wetting agent, a suspending agent, an emulsifier, a sweetening agent, a flavoring agent, a fragrance, a preservative, a buffer and the like.
- Injections for parenteral administration include all injections and also include drops. For example, injections into muscle, subcutaneous injections, intradermal injections, intraarterial injections, intravenous injections, intraperitoneal injections, spinal injections And intravenous drops.
- Injections for parenteral administration include solutions, suspensions, emulsions, and solid injections used by dissolving or suspending in a solvent for use. Injectables are used by dissolving, suspending or emulsifying one or more active substances in a solvent.
- the solvent examples include distilled water for injection, physiological saline, macrogol, vegetable oils (eg, sesame oil, corn oil, olive oil, etc.), alcohols such as propylene glycol, polyethylene glycol, ethanol, and the like.
- the injection further comprises a stabilizing agent (eg, D sorbitol, D mannitol, L-alanine, ascorbic acid, albumin, inositol, sodium dalconate, sodium thioglycolate).
- a stabilizing agent eg, D sorbitol, D mannitol, L-alanine, ascorbic acid, albumin, inositol, sodium dalconate, sodium thioglycolate.
- solubilizers for example, glutamic acid, aspartic acid, polysorbate 80 (registered trademark), polyethylene glycol, propylene dalicol, D-man-tol, benzyl benzoate, ethanol, tris
- Aminomethane cholesterol, triethanolamine, sodium carbonate, sodium citrate, etc.
- emulsifying or suspending agents eg, surfactants (eg, stearyltriethanolamine, sodium lauryl sulfate, laurylamino) Propionic acid, lecithin, benzalco-chloride, benzethonium chloride, glyceryl monostearate, etc.
- hydrophilic polymers eg, polybutyl alcohol, polybutylpyrrolidone, sodium carboxymethyl cellulose, methinoresenolerose, hydrid
- a sterile solid preparation for example, a lyophilized product
- Freeze-drying can be performed by a method known per se. Generally, after freezing at a temperature of -25 ° C or less, the shelf temperature is raised until the temperature of the shelf reaches 25 ° C to 40 ° C while maintaining the degree of vacuum in the drying cabinet at about 13.3Pa or less. Drying method is preferred.
- compositions for parenteral administration include external solutions, ointments, liniments, inhalants, sprays, suppositories and vagina which contain one or more active substances and are formulated in a conventional manner. And pessaries for internal administration.
- Sprays may be used in addition to commonly used diluents to make them isotonic with stabilizers such as sodium bisulfite, for example sodium chloride, sodium citrate or citric acid. It may contain a suitable isotonic agent.
- stabilizers such as sodium bisulfite, for example sodium chloride, sodium citrate or citric acid. It may contain a suitable isotonic agent.
- the method for producing sprays is described in detail in, for example, US Pat. Nos. 2,868,691 and 3,095,355.
- the compound derived from the present invention, a salt thereof, a solvate thereof, or a prodrug thereof is prepared. (1) complement and / or enhance the preventive and Z or therapeutic effects of the compound, (2) improve the kinetics, absorption, decrease the dose of the compound, and (3) side effects of the compound It may be administered as a concomitant drug in combination with another drug for the purpose of, for example, reducing the amount of the drug.
- concomitant drugs in addition, (1) supplementation and / or enhancement of the preventive and Z or therapeutic effects of other concomitant drugs (hereinafter sometimes abbreviated as concomitant drugs), (2) improvement of absorption of kinetics, reduction of dosage And / or Z or (3) a compound, a salt thereof, a solvate thereof, or a prodrug thereof according to the present invention for reducing side effects, which is administered in combination as a concomitant drug.
- the concomitant drug of the present invention, a salt thereof, a solvate thereof, or a prodrug thereof and a concomitant drug may be administered in the form of a combination drug comprising both components in a single preparation. It may be in the form of administration as separate preparations. When administered as such separate preparations, simultaneous administration and administration at different times are included. In addition, the administration by the time difference may be performed by administering the compound derived by the present invention, a salt thereof, a solvate thereof, or a prodrug thereof first, and administering the concomitant drug later, or the concomitant drug first.
- the compound, its salt, its solvate, or its prodrug, which is administered by the present invention, and administered later may be administered without any force, and the respective administration methods may be the same or different.
- Diseases in which a prophylactic and / or therapeutic effect is exhibited by the compound of the present invention, a salt thereof, a solvate thereof, or a concomitant drug thereof and a concomitant drug are not particularly limited. Is a disease that supplements and / or enhances the prophylactic and / or therapeutic effects of its salts, solvates or prodrugs thereof, or complements and / or enhances the prophylactic and / or therapeutic effects of concomitant medications Any disease can be used as long as the disease enhances.
- the weight ratio of the drug is not particularly limited.
- the concomitant drug is not limited to a low molecular compound, and may be a high molecular protein, polypeptide, polynucleotide (DNA, RNA, gene), antisense, decoy, antibody, vaccine, or the like.
- the dose of the concomitant drug can be appropriately determined based on the clinically used dose.
- the present invention The compounding ratio of the compound, its salt, its solvate, or their prodrug and concomitant drug should be appropriately selected depending on the age and weight of the subject, administration method, administration time, target disease, symptoms, combination, etc. Can be.
- the concomitant drug may be used in an amount of 0.01 to 100 parts by weight based on 1 part by weight of the solvate or prodrug thereof.
- the concomitant drug may be arbitrarily administered in any combination of one or more of the following homologous groups and heterogeneous groups at any ratio.
- Other drugs for preventing and supplementing Z or enhancing the effect of LPA receptor agonist on urinary system disease and complementing or enhancing Z or therapeutic effect include other therapeutic agents for urological diseases, for example, a1agonist, ⁇ 2agonist And anticholinergic drugs.
- X 1 agonist includes, for example, midodrine hydrochloride and the like.
- ⁇ 2 agonist includes, for example, clenbuterol hydrochloride and the like.
- Anticholinergic agents include, for example, oxyptinin hydrochloride, shiridani bethanechol , Propiverine hydrochloride, propantheline bromide, methyl benactidium bromide, butyl scopolamine bromide, tolterodine tartrate, trospium chloride, 338-338, UK-112 166-04, KRP-197, darifenacin, YM-905 and the like. .
- Other drugs for preventing and complementing or enhancing Z or therapeutic effects of LPA receptor antagonists against urinary system diseases and for enhancing or enhancing Z or therapeutic effects include other therapeutic agents for urological diseases, for example, a1 antagonist, Choline drugs, 5 ⁇ -reductase inhibitors, and ⁇ or antiandrogen drugs.
- ⁇ 1 antagonists include terazosin hydrochloride, bunazosin hydrochloride, perapidil, tamsulosin hydrochloride, doxazosin mesylate, prazosin hydrochloride, indolamin, naphtovidil, anorefuzosine hydrochloride, AIO-8507L, silodosin and the like.
- anticholinergic agents for example, oxyptinin hydrochloride, Propiverine acid, propanthelin bromide, methyl benactidium bromide, butyl scopolamine bromide, tolterodine tartrate, trospium chloride, Z-338, UK-112166-04, KRP-197, Darifenacin, YM-905 and the like.
- anticholinergic drugs are used only in cases without prostatic hypertrophy. It is mainly used for the treatment of pollakiuria and urinary incontinence without prostatic hypertrophy.
- 5 ⁇ -reductase inhibitors include, for example, finasteride, G-998998, and the like.
- the antiandrogen include oxendrone, osaterone acetate, bicalutamide and the like.
- a compound derived by the present invention By combining a compound derived by the present invention, a salt thereof, a solvate thereof, or a prodrug thereof with a concomitant drug, (1) a compound derived by the present invention, a salt thereof, a solvate thereof, Or the dose can be reduced as compared to the case where the prodrug or the concomitant drug is administered alone.
- a compound derived by the present invention a salt thereof, a solvate thereof, or a prodrug thereof and a concomitant drug.
- a concomitant drug having a different mechanism of action from its salt, its solvate, or its prodrug By selecting a concomitant drug having a different mechanism of action from its salt, its solvate, or its prodrug, it can be used safely for a long period of time, and the treatment period can be set longer.
- the therapeutic effect By selecting a compound, a salt thereof, a solvate thereof, or a concomitant drug having a different mechanism of action from the prodrug derived from the present invention, the therapeutic effect can be sustained.
- an excellent effect such as a synergistic effect can be obtained.
- the use of a compound derived from the present invention, a salt thereof, a solvate thereof, or a prodrug thereof in combination with a concomitant drug is referred to as “the concomitant drug of the present invention”.
- the administration time of the compound derived by the present invention, a salt thereof, a solvate thereof, or a prodrug thereof and a concomitant drug is not limited, and the compound derived by the present invention is not limited.
- a salt thereof, a solvate thereof, or a prodrug thereof or a pharmaceutical composition thereof and a concomitant drug or a pharmaceutical composition thereof may be administered to a subject at the same time or at a time interval.
- the dose of the concomitant drug should be suitable for the administration subject, administration route, disease, combination, etc., according to the clinically used dose. You can choose any.
- the administration form of the concomitant drug of the present invention is not particularly limited as long as the compound derived from the present invention, a salt thereof, a solvate thereof, or a prodrug thereof and a concomitant drug are combined in vivo. .
- Such dosage forms include, for example, (1) a single preparation obtained by simultaneously formulating a compound, a salt thereof, a solvate thereof, or a prodrug thereof, and a concomitant drug derived from the present invention.
- Administration (5) Administration of two compounds obtained by separately formulating a compound, a salt thereof, a solvate thereof, or a prodrug thereof and a concomitant drug derived according to the present invention, by the time difference between different administration routes by different administration routes (For example, a compound derived by the present invention, a salt thereof, a solvate thereof, or a prodrug thereof; administration of the concomitant drug in the order of administration, or administration in the reverse order).
- a compound derived from the present invention, a salt thereof, a solvate thereof, or a compound thereof When administering the concomitant drug of the present invention, a compound derived from the present invention, a salt thereof, a solvate thereof, or a compound thereof according to a means known per se generally used in a method for producing a pharmaceutical preparation.
- These prodrugs and Z or the concomitant drug may be used as they are or as a mixture with a pharmacologically acceptable carrier.
- solid dosage forms for internal use e.g., tablets (including sugar-coated tablets, film-coated tablets), powders, pills, etc.) Preparations, granules, capsules, etc.), orally or parenterally (eg, topically, rectally, intravenously) Administration etc.) can be safely administered.
- Pharmacologically acceptable carriers used in the production of these pharmaceutical preparations include various organic or inorganic carrier substances commonly used as preparation materials, such as excipients in solid preparations, lubricants, and the like. Examples include powders, binders and disintegrants, or solvents in liquids, dissolution aids, emulsifying or suspending agents, isotonic agents, buffers and soothing agents. If necessary, use ordinary preservatives, antioxidants, coloring agents, sweeteners, adsorbents, wetting agents, etc. An appropriate amount of the additive can be used as appropriate.
- Excipients include, for example, ratatose, mannitol, glucose, microcrystalline cellulose, starch, corn starch, light caffeic anhydride and the like.
- binder examples include hydroxypropylcellulose, polyvinylpyrrolidone, magnesium aluminate metasilicate, crystalline cellulose, sucrose, D-mantol, dextrin, hydroxypropylmethylcellulose, starch, sucrose, gelatin, methylcellulose, And carboxymethyl cellulose sodium.
- Disintegrators include, for example, cellulose glycolate, starch, carboxymethylcellulose, carboxymethylcellulose calcium, sodium carboxymethyl starch, L-hydroxypropylcellulose and the like.
- Examples of the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- Examples of the solvent include distilled water for injection, saline, macrogol, vegetable oils (eg, sesame oil, corn oil, olive oil, etc.), alcohols such as propylene glycol, polyethylene glycol, ethanol, and the like. Combinations and the like can be mentioned.
- Examples of the stabilizer include D sorbitol, D mannitol, L-alanine, ascorbic acid, albumin, inositol, sodium dalconate, sodium thioglycolate, and polyoxyethylene hydrogenated castor oil.
- solubilizers include glutamic acid, aspartic acid, polysorbate 80 (registered trademark), polyethylene glycol, propylene glycol, D-mantol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, and the like.
- Sodium carbonate, sodium citrate and the like can be mentioned.
- the emulsifying or suspending agent include surfactants (eg, stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalco-chloride, benzethonium chloride, glyceryl monostearate, etc.).
- Hydrophilic polymers eg, polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethinoresenorelose, hydroxyethinoresenorelose, hydroxypropinoresenorelose, etc.
- the soothing agent include benzyl alcohol and the like.
- the tonicity agent include glucose, D-sorbitol, sodium salt, glycerin, D-mantol and the like.
- As a buffer for example, phosphate, acetate, carbonate And buffers such as citrate.
- Examples of the preservative include parahydroxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- Examples of the antioxidant include sulfite, ascorbic acid, ⁇ -tocopherol and the like.
- the compounding ratio of the compound induced by the present invention, its salt, its solvate, or its prodrug in the concomitant drug of the present invention varies depending on the form of the preparation. It is from 0.01% to about 100% by weight, preferably from about 0.1% to about 50% by weight, more preferably from about 0.5% to about 20% by weight.
- the compounding ratio of the concomitant drug in the concomitant preparation of the present invention varies depending on the form of the preparation, but is usually about 0.01% to about 100% by weight, preferably about 0.1% by weight, based on the whole preparation. To about 50% by weight, more preferably from about 0.5% to about 20% by weight.
- the content of additives such as carriers in the concomitant drug of the present invention varies depending on the form of the preparation, but is usually about 1% to about 99.99% by weight, preferably about 10% to about 9% by weight, based on the whole preparation. About 90% by weight. Similar contents may be used when the compound derived by the present invention, a salt thereof, a solvate thereof, or a prodrug thereof and a concomitant drug are separately formulated.
- a tablet is prepared by granulating a drug as it is or by adding an excipient, a binder, a disintegrant or other appropriate additives, and mixing them uniformly to obtain granules by an appropriate method.
- a tablet is prepared by granulating a drug as it is or by adding an excipient, a binder, a disintegrant or other appropriate additives, and mixing them uniformly to obtain granules by an appropriate method.
- the granules can be produced as they are or by adding an appropriate additive to the granules and mixing them uniformly, followed by compression molding.
- Such tablets may optionally contain a coloring agent, a flavoring agent, and the like.
- the coating can be applied with an appropriate coating agent.
- Injectables are prepared by dissolving, suspending, or emulsifying a certain amount of the drug in an aqueous solvent, water for injection, physiological saline, Ringer's solution, etc. Alternatively, a quantity of the medicinal product can be prepared in a sealed container for injection.
- Carriers used in formulations for oral administration include, for example, starch, mannitol, crystals Substances commonly used in the field of pharmaceuticals such as cellulose and sodium carboxymethylcellulose are used.
- As the carrier used for the preparation for injection for example, distilled water, physiological saline, glucose solution, infusion solution and the like are used.
- additives generally used in preparations can be appropriately added.
- the dose of the concomitant drug of the present invention varies depending on age, body weight, symptom, therapeutic effect, administration method, treatment time and the like. Oral administration once a day, several times a day, in a range of 0.1 mg lOOOOmg per person, or in a range of 0.1mg lOOmg per adult, once a day. It is administered parenterally (preferably intravenously) several times once a day, or is continuously administered intravenously in the range of 1 hour to 24 hours a day.
- the concomitant drug can be used in any amount as long as side effects do not become a problem and the object of the present invention can be achieved.
- the daily dosage of the concomitant drug varies depending on the severity of symptoms, age, sex, weight, sensitivity difference, timing of administration, interval of administration, nature of pharmaceutical preparation, preparation, type, type of active ingredient, etc. There is no particular limitation.
- the concomitant drug When administering the concomitant drug of the present invention, the concomitant drug may be administered at the same time. However, after administering the concomitant drug first, the compound induced by the present invention, a salt thereof, a solvate thereof, or a solvate thereof is obtained. These prodrugs may be administered, or the compound derived from the present invention, a salt thereof, a solvate thereof, or a prodrug thereof may be administered first, and then a concomitant drug may be administered. .
- the time difference varies depending on the active ingredient to be administered, dosage form, and administration method.
- the concomitant drug is administered first, within 1 minute to 3 days after administration of the concomitant drug, preferably examples include a method of administering the compound induced by the present invention within 10 minutes to 1 day, more preferably within 15 minutes to 1 hour.
- a compound derived from the present invention, a salt thereof, a solvate thereof, or a prodrug thereof is previously applied, the compound derived from the present invention, a salt thereof, a solvate thereof, or a prodrug thereof are provided.
- the concomitant drug is administered within 1 minute to 1 day, preferably within 10 minutes to 6 hours, more preferably within 15 minutes to 1 hour. [Pharmacological activity]
- Examples of the screening method of the present invention include the following methods.
- the following screening methods can be used to find LPA receptor agonists or antagonists.
- the method exemplified below uses EDG-2 as the LPA receptor, but other LPA receptors may be used as well.
- EDG-2 The effect on EDG-2 can be evaluated, for example, by the following experiment.
- Hamster Ovary (CHO) cells can be used to evaluate the receptor's agonist and antagonist activities.
- EDG-2 expressing cells were obtained using Ham's F12 medium (manufactured by Gibco) containing 10% FBS ( ⁇ fetal serum), penicillin Z streptomycin, and blasticidin (5 ⁇ g / mL). Incubate.
- FBS ⁇ fetal serum
- penicillin Z streptomycin ⁇ fetal serum
- blasticidin 5 ⁇ g / mL.
- the cells were treated with a Fura2-AM solution [10% FBS, HEPES buffer (20 mM, pH 7.4), probenecid (2.5 mM). , Sigma, No. P-8761) containing Ham, sF12 medium] (5 M) at 37 ° C for 60 minutes, HEPES buffer (20 mM, pH 7.4) and probenecid (2M). Wash once with Hanks solution containing 5 mM) and soak in the same Hanks solution. It is possible to continue evaluation according to the following method (i) or (ii).
- EDG-2 antagonistic activity is the control value (A) of the peak value of highly active LPA in a well containing DMSO without compound and the value before addition of the highly active LPA in cells treated with the compound.
- the IC value is defined as the concentration of the test compound showing 50% inhibition. Can be calculated.
- the plate is set in the above-mentioned fluorescent drug screening system, measured without stimulation for 30 seconds, and a test compound solution is added.
- the compound to be evaluated is dissolved in DMSO or the like, and added so that the final concentration of the DMSO solution will be 1Z1000 at a final concentration in the range of 0. InM to M.
- LPA for example, 18: 3-LPA
- the screening method of the present invention uses a highly active LPA, which is a causative substance of various diseases, as a ligand. It is.
- FIG. 1 shows mass spectrometry data of 1-linolenoyl (18: 3) —LPA and highly active LPA obtained by acidifying it.
- the whole operation was based on basic biological techniques and utilized conventional methods.
- the measurement method of the present invention is used to evaluate a compound derived from the present invention, a salt thereof, a solvate thereof, or a prodrug thereof, as described below. Above and Z or with improved measurement sensitivity. The detailed experimental method is shown below.
- TLC confirmed that no LPA remained in the aqueous layer, and the organic layers were combined and concentrated under reduced pressure.
- Example 1 It was confirmed by mass spectrometry that the highly active LPA obtained in Example 1 was different from 1-linolenoyl (18: 3) -LPA obtained in Reference Example 1. The measurement conditions and methods are shown below.
- Silica gel column Develosil60-5 (2. Omm X 150mm) (Nomura Chemical Co., LTD.)
- Capillary 2.9; Cone: 40; RF Lensl: 50.0; Sourse Temp (° C): 100; Desolvation Temp (° C): 200; Cone Gas Flow (L / Hr): 50; Desolvation Gas Flow (L / (Hr): 800
- HPLC Gradient Parentheses [] indicate the ratio (%) of buffer A to buffer B.
- Capillary 2.9; Cone: 40; RF Lensl: 50.0; Sourse Temp (° C): 100; Desolvation Temp (° C): 200; Cone Gas Flow (L / Hr): 50; Desolvation Gas F low (L / Hr): 800
- the 1-linolenoyl (18: 3) LPA obtained in Reference Example 1 and the highly active LPA obtained in Example 1 showed different spectrum charts (FIG. 1) by mass spectrometry.
- the agonist activity of the receptor was evaluated using Chinese Hamster Ovary (CHO) cells overexpressing the human EDG-2 gene.
- EDG-2 expressing cells were cultured using Ham's F12 medium (Gibco BRL) containing 10% FBS (fetal fetal serum), penicillin Z streptomycin, and blasticidin (5 ⁇ g / mL).
- FBS fetal fetal serum
- penicillin Z streptomycin penicillin Z streptomycin
- blasticidin 5 ⁇ g / mL
- Fura2-AM Dojindo
- the cells were treated with a Fura2-AM solution [10% FBS, HEPES buffer (20 mM, pH 7.4), probenecid (2.5 mM) (Sigma, P -8761) containing Ham, sF12 medium] (5 / zM), incubate at 37 ° C for 60 minutes, contain HEPES buffer (20 mM, pH 7.4) and probenecid (2.5 mM) It was washed once with Hanks solution and immersed in Hanks solution.
- a Fura2-AM solution 10% FBS, HEPES buffer (20 mM, pH 7.4), probenecid (2.5 mM) (Sigma, P -8761) containing Ham, sF12 medium] (5 / zM)
- HEPES buffer 20 mM, pH 7.4
- probenecid 2.5 mM
- the plate was set in a fluorescent drug screening system (manufactured by Hamamatsu Photonitas), measured without stimulation for 30 seconds, and the solution containing the highly active LPA obtained in Example 1 was added.
- LPA was dissolved in physiological saline and added at a final concentration of 0.1 nM to 10 M.
- the intracellular Ca 2+ concentration (Fura2-Ca 2+ fluorescence) before and after the addition was measured at 3-second intervals (excitation wavelengths 340 and 380 nm, emission wavelength 500 nm).
- Example 1 It was found that the highly active LPA obtained in Example 1 had an effect of increasing the intracellular calcium ion concentration in EDG-2 expressing cells.
- IGS rats Female or male CD (SD) IGS rats (Nippon-charlsriver, 8-9 weeks of age) were exsanguinated by head bruising and jugular arteriovenous transection, the urethra below the pubic bone was carefully removed. Immediately use Krebs-Henseleit solution (112 mM NaCl, 5.9 mM KC1, 2.0 mM CaCl2)
- Extirpated specimen force The urethra was cut off, cut into a plate, cut in parallel with the oratoris muscle, and two or three strips of 2 to 3 mm in width and 3 to 4 mm in length were prepared per animal.
- the suspension was suspended in a Magnus tube filled with 22 aeration (volume: 10 mL). After applying a tension load of about 0.5g and stabilizing for 60 minutes, a force displacement transducer (Nihon Kohden, FD pick-up TB-61IT) force A recorder (Nippon Koden, AP-621G) is used for the recorder. The contraction movement was recorded on GRAPHTEC CORP., Linear coder WR3320).
- the contractile response of the control was obtained by stimulating with a high-concentration KC1 solution (Krebs-Henseleit in which all NaCl was replaced with KC1).
- Example 1 The solution containing the highly active LPA obtained in Example 11 or Example 12 was added, and the dose dependence of urethral contraction was measured.
- Example 1-1 Example 1-1 contracts the isolated urethra of the rat in a dose-dependent manner.
- the urethral pressure was adjusted to around 20 mmHg, and the patient was allowed to stand still until it stabilized (about 20 minutes). Thereafter, the highly active LPA obtained in Example 11 or 12 or LPA used as a raw material for producing them was intravenously administered, and the effect of increasing intraurethral pressure was evaluated.
- the highly active LPA showed an activity to increase the intraurethral pressure in the urethra as compared to LPA.
- a comparison between 1-linolenoyl (18: 3) -LPA obtained in Reference Example 1 and the highly active LPA obtained in Example 1 shows that at the dose of 0.3 mgZkg, iv, the highly active LPA was obtained.
- LPA showed at least a 1.5- to 2-fold increase in intraurethral pressure compared to 1-linolenoyl (18: 3) -LPA.
- OmL was added, and after stirring for 5 seconds, methanol (2.5 mL) and acetic acid (60 L) were immediately added and stirred at room temperature for 2 minutes. Further, form (1.25 mL) was added thereto, and the mixture was stirred at room temperature for 1 minute and allowed to stand for 10 minutes.
- Buffer B 10mM ammonium formate (pH 6.4) in methanol
- HPLC Hewlett Packard, HP1100
- LM1 Resolution 15; HM 1 Resolution: 15; Ion Energyl: 0.5; Entrance: -3; Exit: l; LM2 Resolution: 15; HM2 Resolution: 15; Ion Energy2: 3; Multiplier (V): 650; Syringe Pump Flow ( ⁇ L / min): 10; Gas Cell Piran i Pressure (mbar): 2.86E— 03
- Cycle time (sees): 1. 760; Inter Channel delay (sees): 0. 02; Retention window (mins): 0. 000 to 35. 000; Ionization mode: ES—; Data type: M RM data
- HPLC Gradient Parentheses [] indicate the ratio (%) of buffer A to buffer B.
- the oxidized form was specifically and separated from the non-oxidized form under the present analysis conditions, and detected by a tandem mass spectrometer.
- 20: 4-1-8 with one oxygen atom shows a peak area of 113 in the plasma of normal rats, which was below the detection limit (BQL) in blank.
- BQL detection limit
- the present invention can be applied to the medical field as described below.
- a preventive and / or Z or therapeutic substance for a disease associated with LPA can be obtained efficiently.
- the screening method of the present invention is different from the conventional method using LPA. In other words, since highly active LPA, which is a causative substance of various diseases, is used as a ligand, this is a screening method that more closely reflects the biological environment.
- the substance obtained by the screening method of the present invention can be applied as a pharmaceutical.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/584,283 US7700792B2 (en) | 2003-12-26 | 2004-12-22 | Highly active lysophosphatidic acid and method of screening therewith |
JP2005516609A JP4779650B2 (ja) | 2003-12-26 | 2004-12-22 | 高活性型リゾホスファチジン酸およびそれを用いたスクリーニング方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-432844 | 2003-12-26 | ||
JP2003432844 | 2003-12-26 | ||
JP2004-224351 | 2004-07-30 | ||
JP2004224351 | 2004-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005064332A1 true WO2005064332A1 (ja) | 2005-07-14 |
Family
ID=34742136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/019241 WO2005064332A1 (ja) | 2003-12-26 | 2004-12-22 | 高活性型リゾホスファチジン酸およびそれを用いたスクリーニング方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7700792B2 (ja) |
JP (1) | JP4779650B2 (ja) |
WO (1) | WO2005064332A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007140434A2 (en) | 2006-05-31 | 2007-12-06 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
US20120014944A1 (en) * | 2006-05-31 | 2012-01-19 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
US8158124B2 (en) | 2007-05-30 | 2012-04-17 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
US8796429B2 (en) | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
JP2015049050A (ja) * | 2013-08-29 | 2015-03-16 | 花王株式会社 | 排尿障害のバイオマーカー |
AU2012202713B2 (en) * | 2006-05-31 | 2015-04-09 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
KR20140067048A (ko) | 2011-08-15 | 2014-06-03 | 인터뮨, 인크. | 라이소포스파티드산 수용체 길항제 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6380177B1 (en) * | 1999-06-25 | 2002-04-30 | Atairgin Technologies, Inc. | LPA analogs as agonists of the Edg2 LPA receptor |
WO2003007991A1 (fr) * | 2001-07-17 | 2003-01-30 | Ono Pharmaceutical Co., Ltd. | Regulateurs de la secretion de suc pancreatique comprenant un agent de regulation du recepteur a lpa |
JP2003294725A (ja) * | 2002-03-29 | 2003-10-15 | Sumitomo Chem Co Ltd | スクリーニング方法 |
-
2004
- 2004-12-22 WO PCT/JP2004/019241 patent/WO2005064332A1/ja active Application Filing
- 2004-12-22 JP JP2005516609A patent/JP4779650B2/ja not_active Expired - Fee Related
- 2004-12-22 US US10/584,283 patent/US7700792B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6380177B1 (en) * | 1999-06-25 | 2002-04-30 | Atairgin Technologies, Inc. | LPA analogs as agonists of the Edg2 LPA receptor |
WO2003007991A1 (fr) * | 2001-07-17 | 2003-01-30 | Ono Pharmaceutical Co., Ltd. | Regulateurs de la secretion de suc pancreatique comprenant un agent de regulation du recepteur a lpa |
JP2003294725A (ja) * | 2002-03-29 | 2003-10-15 | Sumitomo Chem Co Ltd | スクリーニング方法 |
Non-Patent Citations (1)
Title |
---|
BANDOH K ET AL: "Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors", FEBS LETTERS, vol. 478, 28 July 2000 (2000-07-28), pages 159 - 165, XP004337426 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8796429B2 (en) | 2006-05-31 | 2014-08-05 | Lpath, Inc. | Bioactive lipid derivatives, and methods of making and using same |
US20080145360A1 (en) * | 2006-05-31 | 2008-06-19 | Sabbadini Roger A | Immune-Derived Moieties Reactive Against Lysophosphatidic Acid |
EP2029626A2 (en) * | 2006-05-31 | 2009-03-04 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
EP2029626A4 (en) * | 2006-05-31 | 2010-07-21 | Lpath Inc | GROUPS DERIVED FROM THE IMMUNE SYSTEM WITH REACTIVITY TO LYSOPHOSPHACIDIC ACID |
US20120014944A1 (en) * | 2006-05-31 | 2012-01-19 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
WO2007140434A2 (en) | 2006-05-31 | 2007-12-06 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
AU2012202713B2 (en) * | 2006-05-31 | 2015-04-09 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
US9217749B2 (en) * | 2006-05-31 | 2015-12-22 | Lpath, Inc. | Immune-derived moieties reactive against lysophosphatidic acid |
US9274130B2 (en) * | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
US8158124B2 (en) | 2007-05-30 | 2012-04-17 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
JP2015049050A (ja) * | 2013-08-29 | 2015-03-16 | 花王株式会社 | 排尿障害のバイオマーカー |
Also Published As
Publication number | Publication date |
---|---|
US20070161604A1 (en) | 2007-07-12 |
JP4779650B2 (ja) | 2011-09-28 |
JPWO2005064332A1 (ja) | 2007-12-20 |
US7700792B2 (en) | 2010-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6177401B1 (en) | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis | |
RU2596392C2 (ru) | Антитела против сиглека-15 для лечения заболевания, связанного с потерей костной массы | |
TWI776886B (zh) | Sestrin-gator2交互作用之調節劑及其用途 | |
TWI237022B (en) | Novel acyl-dipeptide-like compounds bearing an accessory functional side chain spacer, a method for preparing the same and pharmaceutical compositions containing such products | |
CN106459079B (zh) | 青蒿素化合物及桥蛋白激动剂的医疗用途 | |
JP6017108B2 (ja) | リゾホスファチジン酸に反応する、免疫により誘導される物質(imune−derivedmoiety) | |
JP2022520518A (ja) | パンテテイン誘導体及びその使用 | |
JP2015013871A (ja) | 新規な生物活性脂質誘導体、それに対して反応性がある免疫により誘導される物質(immune−derivedmoiety)およびその生産および使用方法 | |
JP6023082B2 (ja) | 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物 | |
JP2009539118A (ja) | 生物活性脂質を検出する方法および試薬 | |
WO2005064332A1 (ja) | 高活性型リゾホスファチジン酸およびそれを用いたスクリーニング方法 | |
JP2006070021A (ja) | アナンダミドトランスポーターの阻害剤 | |
JP2018515563A (ja) | 化合物 | |
JP2022538926A (ja) | Ranタンパク質関連神経学的疾患を処置するための方法 | |
JPWO2019208392A1 (ja) | 新規プラズマローゲン誘導体 | |
RU2528333C2 (ru) | Соединения и способы лечения боли и других заболеваний | |
CN108366990A (zh) | 合成的鞘脂类分子、药物、它们的合成方法及治疗方法 | |
CN114698376A (zh) | 作为免疫调节剂的联苯类化合物及其制备方法和应用 | |
US6649655B2 (en) | 11β-fluoro 15β-hydroxy PGF2α analogs as FP receptor antagonists | |
WO2021213518A1 (zh) | 用于预防或治疗脂质代谢相关疾病的化合物 | |
CN115515964A (zh) | 氘代氧化苯砷化合物及其应用 | |
US6492417B1 (en) | 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists | |
Palacios et al. | Expression of adipogenesis markers in a murine stromal cell line treated with 15-deoxy Δ12, 14-prostaglandin J2, interleukin-11, 9-cis retinoic acid and vitamin K2 | |
JPH09500010A (ja) | 一級アミドを加水分解する触媒抗体およびそのような抗体を誘発する方法 | |
WO2021222988A1 (en) | Cell entry-modulating agents and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005516609 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007161604 Country of ref document: US Ref document number: 10584283 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10584283 Country of ref document: US |